Zenth Life Sciences pioneers next-generation therapeutics, precision genomics, and AI-driven drug discovery to accelerate cures and extend healthy human lifespans.
Cross-functional teams leveraging computational biology, synthetic biology, and CRISPR platforms to solve complex diseases.
Multi-omics profiling, hereditary disease mapping, and population-scale genotyping to enable truly personalized treatment pathways.
CRISPR-Cas12 / Base EditingAntibody-drug conjugates, PROTAC degraders, and mRNA-based platforms targeting oncology, autoimmune, and rare diseases.
Oncology / ImmunologyProprietary generative models for molecular design, target identification, and clinical trial optimization reducing lead times by 40%.
Comp Bio / ML PipelinesEngineered cell therapies, microbial factories for sustainable pharmaceuticals, and programmable biomaterials for regenerative medicine.
Cell Engineering / BioFabTransparent tracking of our therapeutic candidates across preclinical validation through regulatory approval.
First-in-class mRNA platform for rapid-response pandemic vaccines and prophylactic oncology immunotherapy.
AAV-based gene replacement therapy for inherited retinal degeneration. Demonstrating 92% efficacy in interim reads.
Bifunctional CAR-T construct for relapsed/refractory solid tumors. Expanding to pancreatic and glioblastoma cohorts.
Allostereic modulator targeting tau protein aggregation in early-stage Alzheimer's and frontotemporal dementia.
State-of-the-art facilities equipped with BSL-3 containment, automated bioprocessing, and high-throughput sequencing.
World-class scientists and industry veterans guiding strategic research and commercialization.
Join our research teams, explore partnership opportunities, or track our pipeline progress.